ExodusPoint Capital Management LP Decreases Holdings in DaVita Inc. (NYSE:DVA)

ExodusPoint Capital Management LP decreased its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 39.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,117 shares of the company's stock after selling 23,399 shares during the period. ExodusPoint Capital Management LP's holdings in DaVita were worth $5,401,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in DVA. FMR LLC increased its holdings in shares of DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company's stock worth $29,082,000 after purchasing an additional 154,061 shares during the period. Captrust Financial Advisors boosted its position in shares of DaVita by 16.6% during the 3rd quarter. Captrust Financial Advisors now owns 3,992 shares of the company's stock worth $654,000 after acquiring an additional 569 shares in the last quarter. Verition Fund Management LLC increased its stake in shares of DaVita by 313.6% in the 3rd quarter. Verition Fund Management LLC now owns 9,603 shares of the company's stock valued at $1,574,000 after purchasing an additional 7,281 shares during the last quarter. Benjamin Edwards Inc. bought a new position in shares of DaVita in the third quarter worth about $207,000. Finally, HighTower Advisors LLC boosted its position in DaVita by 11.3% in the third quarter. HighTower Advisors LLC now owns 23,335 shares of the company's stock valued at $3,813,000 after buying an additional 2,376 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have issued reports on DVA shares. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Thursday. Barclays lifted their price objective on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, DaVita has a consensus rating of "Hold" and an average price target of $166.33.

DaVita Stock Down 1.7 %

NYSE DVA traded down $2.63 during mid-day trading on Thursday, hitting $150.24. The company's stock had a trading volume of 157,302 shares, compared to its average volume of 817,829. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The company's 50 day simple moving average is $153.05 and its 200 day simple moving average is $156.75. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The firm has a market capitalization of $12.02 billion, a price-to-earnings ratio of 13.98, a PEG ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.